Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis

Angiogenesis

Volumn 13, Issue 2, 2010, Pages 161-173

  Strijkers, Gustav J ^a   Kluza, Ewelina ^a   Van Tilborg, Geralda A F ^b   Van Der Schaft, Daisy W J ^a   Griffioen, Arjan W ^c   Mulder, Willem J M ^d   Nicolay, Klaas ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Angiostatic therapy; Liposomes; Magnetic resonance imaging; Molecular imaging; Synergistic targeting; Tumor

Indexed keywords

ANGINEX; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; AVIDIN; BEVACIZUMAB; DISTEAROYLPHOSPHATIDYLCHOLINE; ENDOSTATIN; FLUORODEOXYGLUCOSE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIC ACID; GALECTIN 1; LIPOSOME; MACROGOL 2000; VITRONECTIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; BINDING KINETICS; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; HUMAN; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; DIAGNOSTIC IMAGING; FLUORESCENCE; LIPOSOMES; MAGNETICS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77955655927     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-010-9165-1     Document Type: Review

References (95)

1. RS Kerbel 2008 Tumor angiogenesis N Engl J Med 358 2039 2049 10.1056/NEJMra0706596 18463380 (Pubitemid 351656458)
2. N Ferrara RS Kerbel 2005 Angiogenesis as a therapeutic target Nature 438 967 974 10.1038/nature04483 16355214 (Pubitemid 43093963)
3. KJ Kim B Li J Winer, et al. 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 841 844 10.1038/362841a0 7683111 (Pubitemid 23132159)
4. R Beliveau D Gingras EA Kruger, et al. 2002 The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects Clin Cancer Res 8 1242 1250 11948139
5. MS O'Reilly T Boehm Y Shing, et al. 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 277 285 10.1016/S0092- 8674(00)81848-6 9008168 (Pubitemid 28015876)
6. R Benezra S Rafii 2004 Endostatin's endpoints-deciphering the endostatin antiangiogenic pathway Cancer Cell 5 205 206 10.1016/S1535-6108(04)00057-1 15050911 (Pubitemid 38402111)
7. AW Griffioen DW van der Schaft AF Barendsz-Janson, et al. 2001 Anginex, a designed peptide that inhibits angiogenesis Biochem J 354 233 242 10.1042/0264-6021:3540233 11171099 (Pubitemid 32209858)
8. J Folkman 2004 Endogenous angiogenesis inhibitors APMIS 112 496 507 10.1111/j.1600-0463.2004.apm11207-0809.x 15563312 (Pubitemid 39626056)
9. DW van der Schaft RP Dings QG de Lussanet, et al. 2002 The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models FASEB J 16 1991 1993 12397082
10. AM De Schepper JL Bloem 2007 Soft tissue tumors: grading, staging, and tissue-specific diagnosis Top Magn Reson Imaging 18 431 444 10.1097/rmr. 0b013e3181652220 18303401 (Pubitemid 351315546)
11. Q He RZ Xu P Shkarin, et al. 2003 Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment Dis Markers 19 69 94 15096706
12. J Zhou B Lal DA Wilson, et al. 2003 Amide proton transfer (APT) contrast for imaging of brain tumors Magn Reson Med 50 1120 1126 10.1002/mrm.10651 14648559 (Pubitemid 37494013)
13. TC Kwee T Takahara R Ochiai, et al. 2008 Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology Eur Radiol 18 1937 1952 10.1007/s00330-008-0968-z 18446344
14. H Dafni A Gilead N Nevo, et al. 2003 Modulation of the pharmacokinetics of macromolecular contrast material by avidin chase: MRI, optical, and inductively coupled plasma mass spectrometry tracking of triply labeled albumin Magn Reson Med 50 904 914 10.1002/mrm.10638 14587000 (Pubitemid 37356569)
15. T Barrett H Kobayashi M Brechbiel, et al. 2006 Macromolecular MRI contrast agents for imaging tumor angiogenesis Eur J Radiol 60 353 366 10.1016/j.ejrad.2006.06.025 16930905
16. F Kiessling B Morgenstern C Zhang 2007 Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging Curr Med Chem 14 77 91 10.2174/092986707779313516 17266569 (Pubitemid 46050305)
17. WJ Mulder AW Griffioen GJ Strijkers, et al. 2007 Magnetic and fluorescent nanoparticles for multimodality imaging Nanomedicine (Lond) 2 307 324 10.2217/17435889.2.3.307 (Pubitemid 46923488)
18. K Glunde AP Pathak ZM Bhujwalla 2007 Molecular-functional imaging of cancer: to image and imagine Trends Mol Med 13 287 297 10.1016/j.molmed.2007.05. 002 17544849 (Pubitemid 47017002)
19. DA Sipkins DA Cheresh MR Kazemi, et al. 1998 Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging Nat Med 4 623 626 10.1038/nm0598-623 9585240 (Pubitemid 28237365)
20. PM Winter SD Caruthers A Kassner, et al. 2003 Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel αvβ3- targeted nanoparticle and 1.5 tesla magnetic resonance imaging Cancer Res 63 5838 5843 14522907
21. AM Morawski PM Winter KC Crowder, et al. 2004 Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI Magn Reson Med 51 480 486 10.1002/mrm.20010 15004788 (Pubitemid 38298660)
22. WJ Mulder GJ Strijkers JW Habets, et al. 2005 MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle FASEB J 19 2008 2010 16204353
23. EH Lim N Danthi M Bednarski, et al. 2005 A review: Integrin αvβ3-targeted molecular imaging and therapy in angiogenesis Nanomedicine 1 110 114 17292065
24. WJ Mulder DW van der Schaft PA Hautvast, et al. 2007 Early in vivo assessment of angiostatic therapy efficacy by molecular MRI FASEB J 21 378 383 10.1096/fj.06-6791com 17202248 (Pubitemid 46213485)
25. C Zhang M Jugold EC Woenne, et al. 2007 Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner Cancer Res 67 1555 1562 10.1158/0008-5472.CAN-06-1668 17308094 (Pubitemid 46383379)
26. AH Schmieder SD Caruthers H Zhang, et al. 2008 Three-dimensional MR mapping of angiogenesis with α5β1(αvβ3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model FASEB J 22 4179 4189 10.1096/fj.08-112060 18697838
27. PM Winter AH Schmieder SD Caruthers, et al. 2008 Minute dosages of αvβ3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits FASEB J 22 2758 2767 10.1096/fj.07-103929 18362202
28. F Kiessling J Huppert C Zhang, et al. 2009 RGD-labeled USPIO inhibits adhesion and endocytotic activity of αvβ3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment Radiology 253 462 469 10.1148/radiol.2532081815 19789239
29. NR Soman SL Baldwin G Hu, et al. 2009 Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth J Clin Invest 119 2830 2842 10.1172/JCI38842 19726870
30. M Lijowski S Caruthers G Hu, et al. 2009 High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model Invest Radiol 44 15 22 10.1097/RLI.0b013e31818935eb 18836386
31. VP Torchilin 2007 Targeted pharmaceutical nanocarriers for cancer therapy and imaging AAPS J 9 E128 E147 10.1208/aapsj0902015 17614355
32. AD Bangham MM Standish JC Watkins 1965 Diffusion of univalent ions across the lamellae of swollen phospholipids J Mol Biol 13 238 252 10.1016/S0022-2836(65)80093-6 5859039
33. VP Torchilin 2005 Recent advances with liposomes as pharmaceutical carriers Nat Rev Drug Discov 4 145 160 10.1038/nrd1632 15688077 (Pubitemid 40282557)
34. AL Klibanov K Maruyama VP Torchilin, et al. 1990 Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett 268 235 237 10.1016/0014-5793(90)81016-H 2384160 (Pubitemid 20233874)
35. DC Drummond O Meyer K Hong, et al. 1999 Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol Rev 51 691 743 10581328
36. VJ Caride HD Sostman RJ Winchell, et al. 1984 Relaxation enhancement using liposomes carrying paramagnetic species Magn Reson Imaging 2 107 112 10.1016/0730-725X(84)90064-X 6530919
37. G Navon R Panigel G Valensin 1986 Liposomes containing paramagnetic macromolecules as MRI contrast agents Magn Reson Med 3 876 880 10.1002/mrm.1910030608 2434823
38. RL Magin SM Wright MR Niesman, et al. 1986 Liposome delivery of NMR contrast agents for improved tissue imaging Magn Reson Med 3 440 447 10.1002/mrm.1910030309 3724423
39. SH Koenig RD Brown 3rd R Kurland, et al. 1988 Relaxivity and binding of Mn2+ ions in solutions of phosphatidylserine vesicles Magn Reson Med 7 133 142 10.1002/mrm.1910070202 3398761
40. JM Devoisselle J Vion-Dury JP Galons, et al. 1988 Entrapment of gadolinium-DTPA in liposomes. Characterization of vesicles by P-31 NMR spectroscopy Invest Radiol 23 719 724 10.1097/00004424-198810000-00003 3192394
41. E Unger P Needleman P Cullis, et al. 1988 Gadolinium-DTPA liposomes as a potential MRI contrast agent. Work in progress Invest Radiol 23 928 932 10.1097/00004424-198812000-00010 3203995 (Pubitemid 19008948)
42. C Tilcock E Unger P Cullis, et al. 1989 Liposomal Gd-DTPA: preparation and characterization of relaxivity Radiology 171 77 80 2928549
43. SL Fossheim AK Fahlvik J Klaveness, et al. 1999 Paramagnetic liposomes as MRI contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity Magn Reson Imaging 17 83 89 10.1016/S0730-725X(98)00141-6 9888401 (Pubitemid 29036107)
44. SL Fossheim KA Il'yasov J Hennig, et al. 2000 Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies Acad Radiol 7 1107 1115 10.1016/S1076-6332(00)80064-1 11131055
45. GW Kabalka MA Davis TH Moss, et al. 1991 Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver Magn Reson Med 19 406 415 10.1002/mrm. 1910190231 1881329
46. GW Kabalka MA Davis E Holmberg, et al. 1991 Gadolinium-labeled liposomes containing amphiphilic Gd-DTPA derivatives of varying chain length: targeted MRI contrast enhancement agents for the liver Magn Reson Imaging 9 373 377 10.1016/0730-725X(91)90425-L 1881256
47. PL Anelli L Lattuada V Lorusso, et al. 2001 Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents Magn Res Mater Phys 12 114 120
48. M Oliver A Ahmad N Kamaly, et al. 2006 MAGfect: a novel liposome formulation for MRI labelling and visualization of cells Org Biomol Chem 4 3489 3497 10.1039/b605394g 17036144 (Pubitemid 44319637)
49. N Kamaly T Kalber A Ahmad, et al. 2008 Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging Bioconjug Chem 19 118 129 10.1021/bc7001715 17985841 (Pubitemid 351213842)
50. WJ Mulder GJ Strijkers AW Griffioen, et al. 2004 A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets Bioconjug Chem 15 799 806 10.1021/bc049949r 15264867 (Pubitemid 38981954)
51. GJ Strijkers WJ Mulder RB van Heeswijk, et al. 2005 Relaxivity of liposomal paramagnetic MRI contrast agents Magn Res Mater Phys 18 186 192 10.1007/s10334-005-0111-y (Pubitemid 41428270)
52. S Hak HM Sanders P Agrawal, et al. 2009 A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging Eur J Pharm Biopharm 72 397 404 10.1016/j.ejpb.2008.09.017 18940253
53. JM Idee M Port A Dencausse, et al. 2009 Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update Radiol Clin North Am 47 855 869 10.1016/j.rcl.2009.06.006 19744600 (vii)
54. R Haubner HJ Wester WA Weber, et al. 2001 Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res 61 1781 1785 11280722
55. R Haubner HJ Wester F Burkhart, et al. 2001 Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics J Nucl Med 42 326 336 11216533
56. ML Janssen WJ Oyen I Dijkgraaf, et al. 2002 Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model Cancer Res 62 6146 6151 12414640
57. X Chen M Tohme R Park, et al. 2004 Micro-PET imaging of αvβ3-integrin expression with 18F-labeled dimeric RGD peptide Mol Imaging 3 96 104 10.1162/1535350041464892 15296674
58. X Chen R Park AH Shahinian, et al. 2004 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis Nucl Med Biol 31 179 189 10.1016/j.nucmedbio.2003.10.002 15013483 (Pubitemid 38315112)
59. R Haubner 2006 αvβ3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 33 Suppl 1 54 63 10.1007/s00259-006-0136-0 16791598
60. X Chen R Park M Tohme, et al. 2004 MicroPET and autoradiographic imaging of breast cancer αv-integrin expression using 18F- and 64Cu-labeled RGD peptide Bioconjug Chem 15 41 49 10.1021/bc0300403 14733582 (Pubitemid 38165979)
61. AJ Beer M Schwaiger 2008 Imaging of integrin αvβ3 expression Cancer Metastasis Rev 27 631 644 10.1007/s10555-008-9158-3 18523730
62. SD Caruthers T Cyrus PM Winter, et al. 2009 Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis Wiley Interdiscip Rev Nanomed Nanobiotechnol 1 311 323 10.1002/wnan.9 20049799
63. MM Kaneda S Caruthers GM Lanza, et al. 2009 Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics Ann Biomed Eng 37 1922 1933 10.1007/s10439-009-9643-z 19184435
64. AW Griffioen G Molema 2000 Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Pharmacol Rev 52 237 268 10835101
65. E Ruoslahti MD Pierschbacher 1986 Arg-Gly-Asp: a versatile cell recognition signal Cell 44 517 518 10.1016/0092-8674(86)90259-X 2418980
66. G Thumshirn U Hersel SL Goodman, et al. 2003 Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation Chemistry 9 2717 2725 10.1002/chem.200204304 12772286
67. MB Kok S Hak WJ Mulder, et al. 2009 Cellular compartmentalization of internalized paramagnetic liposomes strongly influences both T1 and T2 relaxivity Magn Reson Med 61 1022 1032 10.1002/mrm.21910 19235908
68. GJ Strijkers S Hak MB Kok, et al. 2009 Three-compartment T1 relaxation model for intracellular paramagnetic contrast agents Magn Reson Med 61 1049 1058 10.1002/mrm.21919 19215042
69. GA Koning RM Schiffelers MH Wauben, et al. 2006 Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis Arthritis Rheum 54 1198 1208 10.1002/art.21719 16575845 (Pubitemid 43672932)
70. GA van Tilborg GJ Strijkers EM Pouget, et al. 2008 Kinetics of avidin-induced clearance of biotinylated bimodal liposomes for improved MR molecular imaging Magn Reson Med 60 1444 1456 10.1002/mrm.21780 19025910
71. GA van Tilborg WJ Mulder DW van der Schaft, et al. 2008 Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes Neoplasia 10 1459 1469 19048124
72. B Schechter R Silberman R Arnon, et al. 1990 Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin Eur J Biochem 189 327 331 10.1111/j.1432-1033.1990.tb15493.x 2186907
73. SF Rosebrough DF Hartley 1996 Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis J Nucl Med 37 1380 1384 8708779
74. VV Sinitsyn AG Mamontova YY Checkneva, et al. 1989 Rapid blood clearance of biotinylated IgG after infusion of avidin J Nucl Med 30 66 69 2911044
75. H Kobayashi H Sakahara M Hosono, et al. 1994 Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor J Nucl Med 35 1677 1684 7931671
76. P Laverman S Zalipsky WJ Oyen, et al. 2000 Improved imaging of infections by avidin-induced clearance of 99mTc-biotin-PEG liposomes J Nucl Med 41 912 918 10809208
77. H Kobayashi S Kawamoto RA Star, et al. 2003 Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase Bioconjug Chem 14 1044 1047 10.1021/bc034064l 13129410 (Pubitemid 37152966)
78. E Kluza DW van der Schaft PA Hautvast, et al. 2010 Synergistic targeting of αvβ3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis Nano Lett 10 52 58 10.1021/nl902659g 19968235
79. RH Adams K Alitalo 2007 Molecular regulation of angiogenesis and lymphangiogenesis Nat Rev Mol Cell Biol 8 464 478 10.1038/nrm2183 17522591 (Pubitemid 46823443)
80. CJ Avraamides B Garmy-Susini JA Varner 2008 Integrins in angiogenesis and lymphangiogenesis Nat Rev Cancer 8 604 617 10.1038/nrc2353 18497750
81. K Laginha D Mumbengegwi T Allen 2005 Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity Biochim Biophys Acta 1711 25 32 10.1016/j.bbamem.2005.02.007 15904660 (Pubitemid 40726397)
82. JM Saul AV Annapragada RV Bellamkonda 2006 A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers J Control Release 114 277 287 10.1016/j.jconrel.2006.05.028 16904220 (Pubitemid 44310813)
83. MA McAteer JE Schneider ZA Ali, et al. 2008 Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide Arterioscler Thromb Vasc Biol 28 77 83 10.1161/ATVBAHA.107.145466 17962629
84. JK Willmann AM Lutz R Paulmurugan, et al. 2008 Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo Radiology 248 936 944 10.1148/radiol.2483072231 18710985
85. WF Westlin 2001 Integrins as targets of angiogenesis inhibition Cancer J 7 Suppl 3 S139 S143 11779085
86. L Josephson CH Tung A Moore, et al. 1999 High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates Bioconjug Chem 10 186 191 10.1021/bc980125h 10077466 (Pubitemid 29147720)
87. DH Levine PP Ghoroghchian J Freudenberg, et al. 2008 Polymersomes: a new multi-functional tool for cancer diagnosis and therapy Methods 46 25 32 10.1016/j.ymeth.2008.05.006 18572025
88. M Manchester P Singh 2006 Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging Adv Drug Deliv Rev 58 1505 1522 10.1016/j.addr.2006.09.014 17118484 (Pubitemid 44829893)
89. DP Cormode PA Jarzyna WJ Mulder, et al. 2010 Modified natural nanoparticles as contrast agents for medical imaging Adv Drug Deliv Rev 62 329 338 10.1016/j.addr.2009.11.005 19900496
90. T Skajaa DP Cormode E Falk, et al. 2010 High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis Arterioscler Thromb Vasc Biol 30 169 176 10.1161/ATVBAHA.108.179275 19815819
91. H Tada H Higuchi TM Wanatabe, et al. 2007 In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice Cancer Res 67 1138 1144 10.1158/0008-5472.CAN-06-1185 17283148
92. R Pasqualini E Koivunen E Ruoslahti 1997 Alpha v integrins as receptors for tumor targeting by circulating ligands Nat Biotechnol 15 542 546 10.1038/nbt0697-542 9181576
93. JD Hood M Bednarski R Frausto, et al. 2002 Tumor regression by targeted gene delivery to the neovasculature Science 296 2404 2407 10.1126/science. 1070200 12089446 (Pubitemid 34734217)
94. OC Farokhzad JM Karp R Langer 2006 Nanoparticle-aptamer bioconjugates for cancer targeting Expert Opin Drug Deliv 3 311 324 10.1517/17425247.3.3.311 16640493 (Pubitemid 43772708)
95. S Muyldermans TN Baral VC Retamozzo, et al. 2009 Camelid immunoglobulins and nanobody technology Vet Immunol Immunopathol 128 178 183 10.1016/j.vetimm.2008.10.299 19026455